On July 24, 2023 : Imugene Limited (ASX: IMU), a clinical stage immunooncology company, reported that its B cell immunotherapy HER-Vaxx and CF33 oncolytic virotherapy CHECKVacc will feature at the upcoming ESMO (Free ESMO Whitepaper) Congress, to be held in Madrid on 20-24 October 2023 (Press release, Imugene, JUL 24, 2023, https://mcusercontent.com/e38c43331936a9627acb6427c/files/cffc5686-3530-0415-25bc-3611c54b3cdd/Imugene_HER_Vaxx_and_CHECKVacc_to_be_Featured_at_ESMO.pdf [SID1234633375]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress is the most influential oncology platform for clinicians, researchers, patient advocates, journalists, and healthcare industry representatives from all over the world.
The abstract titles have been announced for the symposium, with Imugene to feature in the following:
Poster Session
• #4720: HERIZON: A Phase 2 study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine plus standard of care chemotherapy in patients with HER2+ advanced stomach Cancer — dose-dependent anti-cancer antibodies correlating with improved clinical outcome. Presenter: Dr Joshua Tobias, Medical University of Vienna. Poster Session
• #4581: Induction of an Inflammatory Tumor Microenvironment with Oncolytic Virus CF33-hNIS-antiPD-L1 Intratumoral Injection in Patients with Metastatic Triple Negative Breast Cancer (mTNBC). Presenter: Dr Jamie Rand, City of Hope.